What the CE Mark Tells You, and the Six Questions It Does Not Answer

A surgeon choosing between two implantable devices is, whether or not it is framed this way, making a judgement about evidence. The CE mark on the box is a real signal, but it answers a narrower question than it is often read as answering — and knowing which question it answers is what makes the rest of the assessment possible.

What the CE mark under MDR actually certifies

Implantable devices used in breast reconstruction — implants, acellular matrices, meshes — are regulated in the European Union under Regulation (EU) 2017/745, the Medical Device Regulation, which replaced the Medical Device Directive and has applied since May 2021. MDR raised the evidence requirements substantially over the directive it replaced, particularly for high-risk implantable devices.

Three features of that route are worth drawing out, because each is commonly misread.

The notified body is not a government agency. It is an independent organisation designated and monitored by a member state to carry out conformity assessment. It audits the manufacturer’s quality system and assesses the technical documentation and the clinical evaluation.

The clinical evaluation is a structured argument, not a single trial. It assembles clinical data — the manufacturer’s own investigations, published literature, and post-market data — into a demonstration that the device performs as intended and that its risks are acceptable against its benefits.

Post-market surveillance feeds back in. This is the part most often overlooked and arguably the most important under MDR. What happens to the device in real use is required to return to the evaluation, not merely to be filed. The certificate is not the end of the process.

What it does not tell you

The CE mark establishes that a device meets the regulation’s safety and performance requirements for its intended purpose. It does not establish that the device is better than an alternative, that it will suit a particular patient, or that it will perform as well in your hands and your case mix as in the evaluation.

Comparative effectiveness is not what conformity assessment is for. Two certified devices may be certified on entirely different bodies of evidence, and the mark does not distinguish between them.

Six questions that do distinguish between them

Which leaves the clinical assessment, and it is more tractable than it looks — every question has a specific document that answers it, and a manufacturer who cannot produce that document has given you an answer of a different kind.

Two of those deserve expanding.

“In which patients was it studied?” A matrix evaluated largely in subpectoral reconstruction is being used outside the population it was studied in when placed prepectorally, where the loading is entirely different. That is not an argument against doing it — much of surgical practice runs ahead of the evidence — but it should be a conscious extrapolation rather than an assumption.

“Who conducted and funded the study?” Manufacturer funding does not invalidate a study; for a new device there is often no other funder. It does mean the methodology deserves closer reading: how outcomes were defined, whether assessment was blinded, how loss to follow-up was handled, and whether the comparator was chosen to be informative or to be beaten. The framework in reading a breast reconstruction clinical study applies directly.

Registries, and the limits of a single centre

Individual series are too small to detect uncommon complications and too short to characterise long-term performance. Registries address both, and the questions that matter for implantable devices — late capsular contracture, long-term explantation rates, rare associations — are exactly the ones a single centre cannot answer from its own records.

This is also the practical case for contributing to them: the evidence a surgeon wants to consult in ten years is the evidence being entered now. Complication data and its interpretation are discussed in complication rates in implant reconstruction, and what the matrix literature does and does not currently support in the clinical evidence for biological matrices.

Vigilance, and the part surgeons are actually in

Post-market surveillance is not something that happens to a device elsewhere. Under MDR it depends on incidents being reported, and the people positioned to notice a pattern are the clinicians using the device.

The reporting threshold is lower than most surgeons assume. Serious incidents are reportable, and so are device malfunctions and deterioration in characteristics or performance — a matrix that handles differently from previous lots, packaging that fails, a device that does not perform as its instructions describe. None of that requires patient harm to have occurred, and reporting it is not an allegation against the manufacturer.

The reason to take this seriously is that the alternative is already familiar. The complications that eventually reshaped practice around textured implants were visible in individual practices long before they were visible in the aggregate, and the delay was substantially a reporting delay. A signal that is never entered anywhere cannot be detected by anyone.

The same logic applies to a device that has been modified. Significant changes require the notified body to reassess, and a device on its second or third iteration may share a name with the one in the published series without sharing everything else. Asking which version the evidence refers to is a fair question and the technical documentation answers it.

Material origin is a regulatory question too

Devices of animal origin carry additional requirements around sourcing, traceability and viral and prion inactivation, on top of the general route. For a surgeon the relevant questions are what the source material is, how it is processed, and what the processing leaves behind — covered in how biological matrices are processed, bovine pericardium as a matrix material and xenograft versus allograft.

These are also the questions patients ask most often, and being able to answer them plainly matters: is a biological matrix safe is written for that conversation.

The short version

The CE mark answers “does this device meet the regulation’s requirements for its intended purpose”. It does not answer “is this the right device for this patient”, and no regulatory process will. That second question is answered by six documents, and by knowing which one you are actually being shown.

This article is educational material for clinicians and is a general orientation to the European regulatory framework, not regulatory or legal advice. Regulatory requirements change and vary by jurisdiction; manufacturers and notified bodies are the authoritative source for any specific device.